BioCryst Pharmaceuticals Files Q3 2024 10-Q
Ticker: BCRX · Form: 10-Q · Filed: Nov 5, 2024 · CIK: 882796
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials
Related Tickers: BCRX
TL;DR
BCRX Q3 2024 10-Q filed. Check financials.
AI Summary
BioCryst Pharmaceuticals Inc. reported its third-quarter 2024 results, ending September 30, 2024. The company's financial statements and operational details are presented in this 10-Q filing. Specific financial figures and operational highlights for the period are detailed within the document.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for BioCryst Pharmaceuticals, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, BioCryst faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20240930 — Period End Date (Third quarter of 2024)
- 20230930 — Prior Year Period End Date (Third quarter of 2023)
Key Players & Entities
- BIOCRYST PHARMACEUTICALS INC (company) — Filer
- 20240930 (date) — Period of Report
- 20241105 (date) — Filing Date
- DURHAM (location) — Company Headquarters
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240930, indicating the filing covers the period ending September 30, 2024.
When was this 10-Q filing submitted to the SEC?
The filing was submitted on 20241105.
What is the primary business of BioCryst Pharmaceuticals Inc. according to the filing?
The Standard Industrial Classification code indicates the company is in 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Where is BioCryst Pharmaceuticals Inc. headquartered?
The company's business address is listed as 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC 27703.
What fiscal year end does BioCryst Pharmaceuticals Inc. observe?
The company's fiscal year ends on 1231.
Filing Stats: 4,659 words · 19 min read · ~16 pages · Grade level 18.5 · Accepted 2024-11-05 17:19:10
Key Financial Figures
- $0.01 B — ich registered Common Stock, par value $0.01 BCRX Nasdaq Global Select Market Indica
Filing Documents
- bcrx-20240930.htm (10-Q) — 1561KB
- biocrystpharmaceuticalsinc.htm (EX-10.1) — 17KB
- bcrx-20240930xexx311.htm (EX-31.1) — 9KB
- bcrx-20240930xexx312.htm (EX-31.2) — 9KB
- bcrx-20240930xexx321.htm (EX-32.1) — 5KB
- bcrx-20240930xexx322.htm (EX-32.2) — 5KB
- 0001628280-24-045364.txt ( ) — 8212KB
- bcrx-20240930.xsd (EX-101.SCH) — 60KB
- bcrx-20240930_cal.xml (EX-101.CAL) — 66KB
- bcrx-20240930_def.xml (EX-101.DEF) — 252KB
- bcrx-20240930_lab.xml (EX-101.LAB) — 722KB
- bcrx-20240930_pre.xml (EX-101.PRE) — 488KB
- bcrx-20240930_htm.xml (XML) — 1192KB
Financial Information
Part I. Financial Information 1
Financial Statements ( Unaudited )
Item 1. Financial Statements ( Unaudited ) : 1 Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023 2 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 3 Condensed Consolidated Statements of Stockholders' Deficit for the Three and Nine Months Ended September 30, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 6
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 32
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 45
Controls and Procedures
Item 4. Controls and Procedures 46
Other Information
Part II. Other Information 47
Risk Factors
Item 1A. Risk Factors 47
Other Information
Item 5. Other Information 75
Exhibits
Item 6. Exhibits 76
Signatures
Signatures 77 EX-10.1 EX-31.1 EX-31.2 EX-32.1 EX-32.2 Table of Co n tents When used in this report, unless otherwise indicated, " we, " " our, " " us, " the " Company, " and " BioCryst " refer to BioCryst Pharmaceuticals, Inc. and, where appropriate, its subsidiaries. Cautionary Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q (this "report") includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject to the "safe harbor" created in Section 21E. In particular, statements about our expectations, beliefs, plans, objectives or assumptions of future events or performance are contained or incorporated by reference in this report. All statements other than statements of historical facts contained herein are forward-looking statements. These forward-looking statements can generally be identified by the use of words such as "may," "will," "intends," "plans," "believes," "anticipates," "expects," "estimates," "predicts," "potential," the negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions containing these forward-looking statements are principally contained in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of this report, as well as any amendments we make to those sections in filings with the Securities and Exchange Commission ("SEC"). These forward-looking statements include, but are not limited to, statements about: the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX17725, and early-stage discovery programs (including avoralstat and our complement inhibitors), and our plans regardin
FINANCIAL INFORMATION
PART I. FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements BIOCRYST PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value amounts, Unaudited) September 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 96,841 $ 110,643 Restricted cash 813 1,804 Investments 233,172 278,344 Trade receivables 72,456 56,950 Inventory, net 7,562 28,683 Prepaid expenses and other current assets 16,281 19,542 Total current assets 427,125 495,966 Long-term inventory, net 21,633 — Property and equipment, net 7,421 7,910 Long-term investments 19,426 — Other assets 15,649 13,084 Total assets $ 491,254 $ 516,960 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable $ 13,482 $ 20,893 Accrued expenses 104,197 102,882 Operating lease liabilities 1,049 1,058 Finance lease liabilities 1,839 1,590 Royalty financing obligations 33,000 23,565 Total current liabilities 153,567 149,988 Operating lease liabilities 8,065 8,390 Finance lease liabilities 2,077 2,845 Royalty financing obligations 481,775 508,034 Secured term loan 314,333 303,231 Total liabilities 959,817 972,488 Stockholders' deficit: Preferred stock, $ 0.01 par value; shares authorized - 5,000 ; no shares issued and outstanding at September 30, 2024 and December 31, 2023 — — Common stock, $ 0.01 par value; shares authorized - 450,000 ; shares issued and outstanding – 207,119 at September 30, 2024 and 205,771 at December 31, 2023 2,071 2,058 Additional paid-in capital 1,270,318 1,222,236 Accumulated other comprehensive income 2,293 1,337 Accumulated deficit ( 1,743,245 ) ( 1,681,159 ) Total stockholders' deficit ( 468,563 ) ( 455,528 ) Total liabilities and stockholders' deficit $ 491,254 $ 516,960 See accompanying notes to condensed consolidated financial statements. 1 Table of Co n tents BIOCRYST PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In thousands, except per share amounts, Unaudited) Three